Clinical Management of Anemia in Patients with Myelodysplastic Syndromes: An Update on Emerging Therapeutic Options

References

• Cazzola M. Myelodysplastic syndromes. N Engl J Med. 2020;383(14):1358–1374. doi:10.1056/NEJMra190479432997910
   PubMed Web of Science ®Google Scholar
• Zeidan AM, Faltas B, Douglas Smith B, Gore S. Myelodysplastic syndromes: what do hospitalists need to know? J Hosp Med. 2013;8(6):351–357. doi:10.1002/jhm.204923666619
   PubMed Web of Science ®Google Scholar
• Platzbecker U. Treatment of MDS. Blood. 2019;133(10):1096–1107. doi:10.1182/blood-2018-10-84469630670446
   PubMed Web of Science ®Google Scholar
• Nazha A, Sekeres MA, Gore SD, Zeidan AM. Molecular testing in myelodysplastic syndromes for the practicing oncologist: will the progress fulfill the promise? Oncologist. 2015;20(9):1069–1076. doi:10.1634/theoncologist.2015-006726194858
   PubMed Web of Science ®Google Scholar
• Hong M, The HG. 2016 Revision to the world health organization classification of myelodysplastic syndromes. J Transl Int Med. 2017;5(3):139–143. doi:10.1515/jtim-2017-000229085786
   PubMed Web of Science ®Google Scholar
• Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997;89(6):2079–2088. doi:10.1182/blood.V89.6.20799058730
   PubMed Web of Science ®Google Scholar
• Greenberg PL, Tuechler H, Schanz J, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood. 2012;120(12):2454–2465. doi:10.1182/blood-2012-03-42048922740453
   PubMed Web of Science ®Google Scholar
• Zeidan AM, Gore SD, Komrokji RS. Higher-risk myelodysplastic syndromes with del (5q): is sequential azacitidine-lenalidomide combination the way to go? Expert Rev Hematol. 2013;6(3):251–254. doi:10.1586/ehm.13.3023782079
   PubMed Web of Science ®Google Scholar
• Malcovati L, Hellström-Lindberg E, Bowen D, et al. Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet. Blood. 2013;122(17):2943–2964.23980065
   PubMed Web of Science ®Google Scholar
• NCCN. Myelodysplastic Syndromes (Version 2.2020). Available from: https://www.nccn.org/professionals/physician_gls/pdf/mds.pdf. Accessed 91, 2020.
   Google Scholar
• Pfeilstöcker M, Tuechler H, Sanz G, et al. Time-dependent changes in mortality and transformation risk in MDS. Blood. 2016;128(7):902–910. doi:10.1182/blood-2016-02-70005427335276
   PubMed Web of Science ®Google Scholar
• Zeidan AM, Sekeres MA, Wang XF, et al. Comparing the prognostic value of risk stratifying models for patients with lower-risk myelodysplastic syndromes: is one model better? Am J Hematol. 2015;90(11):1036–1040. doi:10.1002/ajh.2417326284571
   PubMed Web of Science ®Google Scholar
• Zeidan AM, Al Ali N, Barnard J, et al. Comparison of clinical outcomes and prognostic utility of risk stratification tools in patients with therapy-related vs de novo myelodysplastic syndromes: a report on behalf of the MDS Clinical Research Consortium. Leukemia. 2017;31(6):1391–1397. doi:10.1038/leu.2017.3328111463
   PubMed Web of Science ®Google Scholar
• Zeidan AM, Sekeres MA, Barnard J, Steensma DP, Komrokji R. Therapy-related myelodysplastic syndromes-specific risk stratification: are we putting the cart before the horse? Leukemia. 2017;31(11):2539–2541. doi:10.1038/leu.2017.23828757618
   PubMed Web of Science ®Google Scholar
• Zeidan AM, Sekeres MA, Garcia-Manero G, et al. Comparison of risk stratification tools in predicting outcomes of patients with higher-risk myelodysplastic syndromes treated with azanucleosides. Leukemia. 2016;30(3):649–657. doi:10.1038/leu.2015.28326464171
   PubMed Web of Science ®Google Scholar
• Zeidan AM, Stahl M, Hu X, et al. Long-term survival of older patients with MDS treated with HMA therapy without subsequent stem cell transplantation. Blood. 2018;131(7):818–821. doi:10.1182/blood-2017-10-81172929259002
   PubMed Web of Science ®Google Scholar
• Abou Zahr A, Saad Aldin E, Barbarotta L, Podoltsev N, Zeidan AM. The clinical use of DNA methyltransferase inhibitors in myelodysplastic syndromes. Expert Rev Anticancer Ther. 2015;15(9):1019–1036. doi:10.1586/14737140.2015.106193626292903
   PubMed Web of Science ®Google Scholar
• Lee EJ, Zeidan AM. Genome sequencing in myelodysplastic syndromes: can molecular mutations predict benefit from hypomethylating agent therapy? Expert Rev Hematol. 2015;8(2):155–158. doi:10.1586/17474086.2015.101690525697572
   PubMed Web of Science ®Google Scholar
• Fenaux P, Mufti GJ, Santini V, et al. Azacitidine (AZA) treatment prolongs Overall Survival (OS) in higher-risk MDS patients compared with Conventional Care Regimens (CCR): results of the AZA-001 Phase III Study. Blood. 2007;110(11):817. doi:10.1182/blood.V110.11.817.817
   Web of Science ®Google Scholar
• Richard-Carpentier G, DeZern AE, Takahashi K, et al. Preliminary results from the phase II study of the IDH2-inhibitor enasidenib in patients with high-risk IDH2-mutated Myelodysplastic Syndromes (MDS). Blood. 2019;134(Supplement_1):678. doi:10.1182/blood-2019-13050131243042
   PubMed Web of Science ®Google Scholar
• DiNardo CD, Watts JM, Stein EM, et al. Ivosidenib (AG-120) induced durable remissions and transfusion independence in patients with IDH1-mutant relapsed or refractory myelodysplastic syndrome: results from a phase 1 dose escalation and expansion study. Blood. 2018;132(Supplement 1):1812. doi:10.1182/blood-2018-99-111264
   Web of Science ®Google Scholar
• Bewersdorf JP, Zeidan AM. Following in the footsteps of acute myeloid leukemia: are we witnessing the start of a therapeutic revolution for higher-risk myelodysplastic syndromes? Leuk Lymphoma. 2020;61(10):2295–2312. doi:10.1080/10428194.2020.176196832421403
   PubMed Web of Science ®Google Scholar
• Abou Zahr A, Bernabe Ramirez C, Wozney J, Prebet T, Zeidan AM. New Insights into the Pathogenesis of MDS and the rational therapeutic opportunities. Expert Rev Hematol. 2016;9(4):377–388. doi:10.1586/17474086.2016.113504726734762
   PubMed Web of Science ®Google Scholar
• Bewersdorf JP, Zeidan AM. Transforming growth factor (TGF)-β pathway as a therapeutic target in lower risk myelodysplastic syndromes. Leukemia. 2019;33(6):1303–1312. doi:10.1038/s41375-019-0448-230962581
   PubMed Web of Science ®Google Scholar
• Hendrick F, Davidoff AJ, Zeidan AM, Gore SD, Baer MR. Effect of erythropoiesis-stimulating agent policy decisions on off-label use in myelodysplastic syndromes. Medicare Medicaid Res Rev. 2014;4:4. doi:10.5600/mmrr.004.04.a02
   Google Scholar
• Shallis RM, Chokr N, Stahl M, Pine AB, Zeidan AM. Immunosuppressive therapy in myelodysplastic syndromes: a borrowed therapy in search of the right place. Expert Rev Hematol. 2018;11(9):715–726. doi:10.1080/17474086.2018.150304930024293
   PubMed Web of Science ®Google Scholar
• Shallis RM, Xu ML, Podoltsev NA, et al. Be careful of the masquerades: differentiating secondary myelodysplasia from myelodysplastic syndromes in clinical practice. Ann Hematol. 2018;97(12):2333–2343. doi:10.1007/s00277-018-3474-730109425
   PubMed Web of Science ®Google Scholar
• Fong T, Vij R, Vijayan A, DiPersio J, Blinder M. Copper deficiency: an important consideration in the differential diagnosis of myelodysplastic syndrome. Haematologica. 2007;92(10):1429–1430. doi:10.3324/haematol.1131418024379
   PubMed Web of Science ®Google Scholar
• Gregg XT, Reddy V, Prchal JT. Copper deficiency masquerading as myelodysplastic syndrome. Blood. 2002;100(4):1493–1495. doi:10.1182/blood-2002-01-025612149237
   PubMed Web of Science ®Google Scholar
• Bewersdorf JP, Zeidan AM. Evolving therapies for lower-risk myelodysplastic syndromes. Ann Hematol. 2020;99(4):677–692. doi:10.1007/s00277-020-03963-132078008
   PubMed Web of Science ®Google Scholar
• Gupta P, LeRoy SC, Luikart SD, Bateman A, Morrison VA. Long-term blood product transfusion support for patients with myelodysplastic syndromes (MDS): cost analysis and complications. Leuk Res. 1999;23(10):953–959. doi:10.1016/S0145-2126(99)00113-710573142
   PubMed Web of Science ®Google Scholar
• Zeidan AM, Gore SD, Padron E, Komrokji RS. Current state of prognostication and risk stratification in myelodysplastic syndromes. Curr Opin Hematol. 2015;22(2):146–154. doi:10.1097/MOH.000000000000011025575032
   PubMed Web of Science ®Google Scholar
• Gattermann N. Iron overload in myelodysplastic syndromes (MDS). Int J Hematol. 2018;107(1):55–63. doi:10.1007/s12185-017-2367-129177643
   PubMed Web of Science ®Google Scholar
• Koutsavlis I. Transfusion thresholds, quality of life, and current approaches in myelodysplastic syndromes. Anemia. 2016;2016:8494738. doi:10.1155/2016/849473827195147
   PubMed Web of Science ®Google Scholar
• Malcovati L, Della Porta MG, Strupp C, et al. Impact of the degree of anemia on the outcome of patients with myelodysplastic syndrome and its integration into the WHO classification-based prognostic scoring system (WPSS). Haematologica. 2011;96(10):1433–1440. doi:10.3324/haematol.2011.04460221659359
   PubMed Web of Science ®Google Scholar
• Abel GA, Klepin HD, Magnavita ES, et al. Feasibility of peri-transfusion quality of life assessment for patients with myelodysplastic syndromes. Blood. 2020;136(Supplement 1):25–26.
   Google Scholar
• Tanasijevic AM, Revette A, Klepin HD, et al. Consensus minimum hemoglobin level above which patients with myelodysplastic syndromes can safely forgo transfusions. Leuk Lymphoma. 2020;1–5.
   Web of Science ®Google Scholar
• Schafer AI, Cheron RG, Dluhy R, et al. Clinical consequences of acquired transfusional iron overload in adults. N Engl J Med. 1981;304(6):319–324. doi:10.1056/NEJM1981020530406036777701
   PubMed Web of Science ®Google Scholar
• Jensen PD, Jensen FT, Christensen T, Nielsen JL, Ellegaard J. Relationship between hepatocellular injury and transfusional iron overload prior to and during iron chelation with desferrioxamine: a study in adult patients with acquired anemias. Blood. 2003;101(1):91–96. doi:10.1182/blood-2002-06-170412393528
   PubMed Web of Science ®Google Scholar
• Malcovati L. Impact of transfusion dependency and secondary iron overload on the survival of patients with myelodysplastic syndromes. Leuk Res. 2007;31(Suppl 3):S2–6. doi:10.1016/S0145-2126(07)70459-918037415
   PubMed Web of Science ®Google Scholar
• Zeidan AM, Griffiths EA. To chelate or not to chelate in MDS: that is the question! Blood Rev. 2018;32(5):368–377. doi:10.1016/j.blre.2018.03.00229602612
   PubMed Web of Science ®Google Scholar
• Zeidan AM, Pullarkat VA, Komrokji RS. Overcoming barriers to treating iron overload in patients with lower-risk myelodysplastic syndrome. Crit Rev Oncol Hematol. 2017;117:57–66. doi:10.1016/j.critrevonc.2017.07.00228807236
   PubMed Web of Science ®Google Scholar
• Leitch HA, Parmar A, Wells RA, et al. Overall survival in lower IPSS risk MDS by receipt of iron chelation therapy, adjusting for patient-related factors and measuring from time of first red blood cell transfusion dependence: an MDS-CAN analysis. Br J Haematol. 2017;179(1):83–97. doi:10.1111/bjh.1482528677895
   PubMed Web of Science ®Google Scholar
• Remacha ÁF, Arrizabalaga B, Villegas A, et al. Evolution of iron overload in patients with low-risk myelodysplastic syndrome: iron chelation therapy and organ complications. Ann Hematol. 2015;94(5):779–787. doi:10.1007/s00277-014-2274-y25516455
   PubMed Web of Science ®Google Scholar
• Mitchell M, Gore SD, Zeidan AM. Iron chelation therapy in myelodysplastic syndromes: where do we stand? Expert Rev Hematol. 2013;6(4):397–410. doi:10.1586/17474086.2013.81445623991926
   PubMed Web of Science ®Google Scholar
• Zeidan AM, Giri S, DeVeaux M, Ballas SK, Duong VH. Systematic review and meta-analysis of the effect of iron chelation therapy on overall survival and disease progression in patients with lower-risk myelodysplastic syndromes. Ann Hematol. 2019;98(2):339–350. doi:10.1007/s00277-018-3539-730413901
   PubMed Web of Science ®Google Scholar
• Zeidan AM, Hendrick F, Friedmann E, et al. Deferasirox therapy is associated with reduced mortality risk in a medicare population with myelodysplastic syndromes. J Comp Eff Res. 2015;4(4):327–340. doi:10.2217/cer.15.2026274794
   PubMed Web of Science ®Google Scholar
• Angelucci E, Li J, Greenberg P, et al. Iron chelation in transfusion-dependent patients with low- to intermediate-1-risk myelodysplastic syndromes: a randomized trial. Ann Intern Med. 2020;172(8):513–522. doi:10.7326/M19-091632203980
   PubMed Web of Science ®Google Scholar
• Duong VH, Baer MR, Hendrick F, et al. Variations in erythropoiesis-stimulating agent administration in transfusion-dependent myelodysplastic syndromes impact response. Leuk Res. 2015;39(6):586–591. doi:10.1016/j.leukres.2015.03.01325869077
   PubMed Web of Science ®Google Scholar
• Greenberg PL, Sun Z, Miller KB, et al. Treatment of myelodysplastic syndrome patients with erythropoietin with or without granulocyte colony-stimulating factor: results of a prospective randomized phase 3 trial by the Eastern Cooperative Oncology Group (E1996). Blood. 2009;114(12):2393–2400. doi:10.1182/blood-2009-03-21179719564636
   PubMed Web of Science ®Google Scholar
• Cheson BD, Bennett JM, Kantarjian H, et al. Report of an international working group to standardize response criteria for myelodysplastic syndromes. Blood. 2000;96(12):3671–3674.11090046
   PubMed Web of Science ®Google Scholar
• Jädersten M, Malcovati L, Dybedal I, et al. Erythropoietin and granulocyte-colony stimulating factor treatment associated with improved survival in myelodysplastic syndrome. J Clin Oncol. 2008;26(21):3607–3613. doi:10.1200/JCO.2007.15.490618559873
   PubMed Web of Science ®Google Scholar
• Musto P, Lanza F, Balleari E, et al. Darbepoetin alpha for the treatment of anaemia in low-intermediate risk myelodysplastic syndromes. Br J Haematol. 2005;128(2):204–209. doi:10.1111/j.1365-2141.2004.05288.x15638854
   PubMed Web of Science ®Google Scholar
• Mannone L, Gardin C, Quarre MC, et al. High-dose darbepoetin alpha in the treatment of anaemia of lower risk myelodysplastic syndrome results of a phase II study. Br J Haematol. 2006;133(5):513–519. doi:10.1111/j.1365-2141.2006.06070.x16681638
   PubMed Web of Science ®Google Scholar
• Platzbecker U, Symeonidis A, Oliva EN, et al. A phase 3 randomized placebo-controlled trial of darbepoetin alfa in patients with anemia and lower-risk myelodysplastic syndromes. Leukemia. 2017;31(9):1944–1950. doi:10.1038/leu.2017.19228626220
   PubMed Web of Science ®Google Scholar
• Fenaux P, Santini V, Spiriti MAA, et al. A phase 3 randomized, placebo-controlled study assessing the efficacy and safety of epoetin-α in anemic patients with low-risk MDS. Leukemia. 2018;32(12):2648–2658. doi:10.1038/s41375-018-0118-929895954
   PubMed Web of Science ®Google Scholar
• Bohlius J, Bohlke K, Castelli R, et al. Management of cancer-associated anemia with erythropoiesis-stimulating agents: ASCO/ASH clinical practice guideline update. J Clin Oncol. 2019;37(15):1336–1351. doi:10.1200/JCO.18.0214230969847
   PubMed Web of Science ®Google Scholar
• Park S, Kelaidi C, Meunier M, Casadevall N, Gerds AT, Platzbecker U. The prognostic value of serum erythropoietin in patients with lower-risk myelodysplastic syndromes: a review of the literature and expert opinion. Ann Hematol. 2020;99(1):7–19. doi:10.1007/s00277-019-03799-431650290
   PubMed Web of Science ®Google Scholar
• Davidoff AJ, Hendrick FB, Zeidan AM, et al. Patient cost sharing and receipt of erythropoiesis-stimulating agents through medicare part D. J Oncol Pract. 2015;11(2):e190–198. doi:10.1200/JOP.2014.00152725563701
   PubMed Web of Science ®Google Scholar
• Davidoff AJ, Weiss SR, Baer MR, et al. Patterns of erythropoiesis-stimulating agent use among Medicare beneficiaries with myelodysplastic syndromes and consistency with clinical guidelines. Leuk Res. 2013;37(6):675–680. doi:10.1016/j.leukres.2013.02.02123523473
   PubMed Web of Science ®Google Scholar
• Nair V, Mishra DK, Sharma A, et al. Erythropoetin (EPO) and granulocyte colony stimulating factor (GCS-F) based therapy in patients with low risk mds: a single centre experience from India. Blood. 2006;108(11):4869. doi:10.1182/blood.V108.11.4869.4869
   Web of Science ®Google Scholar
• Balleari E, Rossi E, Clavio M, et al. Erythropoietin plus granulocyte colony-stimulating factor is better than erythropoietin alone to treat anemia in low-risk myelodysplastic syndromes: results from a randomized single-centre study. Ann Hematol. 2006;85(3):174–180. doi:10.1007/s00277-005-0044-616408206
   PubMed Web of Science ®Google Scholar
• Mundle S, Lefebvre P, Vekeman F, Duh MS, Rastogi R, Moyo V. An assessment of erythroid response to epoetin alpha as a single agent versus in combination with granulocyte- or granulocyte-macrophage-colony-stimulating factor in myelodysplastic syndromes using a meta-analysis approach. Cancer. 2009;115(4):706–715. doi:10.1002/cncr.2409019152429
   PubMed Web of Science ®Google Scholar
• Affentranger L, Bohlius J, Hallal M, Bonadies N. Efficacy of granulocyte colony stimulating factor in combination with erythropoiesis stimulating agents for treatment of anemia in patients with lower risk myelodysplastic syndromes: A systematic review. Crit Rev Oncol Hematol. 2019;136:37–47. doi:10.1016/j.critrevonc.2019.01.02130878127
   PubMed Web of Science ®Google Scholar
• Suragani RN, Cadena SM, Cawley SM, et al. Transforming growth factor-β superfamily ligand trap ACE-536 corrects anemia by promoting late-stage erythropoiesis. Nat Med. 2014;20(4):408–414. doi:10.1038/nm.351224658078
   PubMed Web of Science ®Google Scholar
• Suragani RN, Cawley SM, Li R, et al. Modified activin receptor IIB ligand trap mitigates ineffective erythropoiesis and disease complications in murine β-thalassemia. Blood. 2014;123(25):3864–3872. doi:10.1182/blood-2013-06-51123824795345
   PubMed Web of Science ®Google Scholar
• Platzbecker U, Germing U, Gotze KS, et al. Luspatercept for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes (PACE-MDS): a multicentre, open-label phase 2 dose-finding study with long-term extension study. Lancet Oncol. 2017;18(10):1338–1347. doi:10.1016/S1470-2045(17)30615-028870615
   PubMed Web of Science ®Google Scholar
• Fenaux P, Platzbecker U, Mufti GJ, et al. Luspatercept in patients with lower-risk myelodysplastic syndromes. N Engl J Med. 2020;382(2):140–151. doi:10.1056/NEJMoa190889231914241
   PubMed Web of Science ®Google Scholar
• Administration FD. FDA approves luspatercept-aamt for anemia in adults with MDS; 2020 Available from: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-luspatercept-aamt-anemia-adults-mds. Accessed 101, 2020.
   Google Scholar
• Stahl M, Zeidan AM. Lenalidomide use in myelodysplastic syndromes: insights into the biologic mechanisms and clinical applications. Cancer. 2017;123(10):1703–1713.28192601
   PubMed Web of Science ®Google Scholar
• Shallis RM, Zeidan AM. Lenalidomide in non-deletion 5q lower-risk myelodysplastic syndromes: a glass quarter full or three quarters empty? Leuk Lymphoma. 2018;59(9):2015–2017. doi:10.1080/10428194.2018.143079729411698
   PubMed Web of Science ®Google Scholar
• Stahl M, Zeidan AM. Management of lower-risk myelodysplastic syndromes without del5q: current approach and future trends. Expert Rev Hematol. 2017;10(4):345–364. doi:10.1080/17474086.2017.129770428277851
   PubMed Web of Science ®Google Scholar
• Bejar R, Levine R, Ebert BL. Unraveling the molecular pathophysiology of myelodysplastic syndromes. J clin oncol. 2011;29(5):504–515. doi:10.1200/JCO.2010.31.117521220588
   PubMed Web of Science ®Google Scholar
• Pozdnyakova O, Miron PM, Tang G, et al. Cytogenetic abnormalities in a series of 1029 patients with primary myelodysplastic syndromes: a report from the US with a focus on some undefined single chromosomal abnormalities. Cancer. 2008;113(12):3331–3340.18988232
   PubMed Web of Science ®Google Scholar
• Solé E, Sanz, et al. Incidence, characterization and prognostic significance of chromosomal abnormalities in 640 patients with primary myelodysplastic syndromes. Br J Haematol. 2000;108(2):346–356. doi:10.1046/j.1365-2141.2000.01868.x10691865
   PubMed Web of Science ®Google Scholar
• Kelaidi C, Park S, Brechignac S, et al. Treatment of myelodysplastic syndromes with 5q deletion before the lenalidomide era; the GFM experience with EPO and thalidomide. Leuk Res. 2008;32(7):1049–1053. doi:10.1016/j.leukres.2007.11.03718191202
   PubMed Web of Science ®Google Scholar
• Park S, Grabar S, Kelaidi C, et al. Predictive factors of response and survival in myelodysplastic syndrome treated with erythropoietin and G-CSF: the GFM experience. Blood. 2008;111(2):574–582. doi:10.1182/blood-2007-06-09637017940203
   PubMed Web of Science ®Google Scholar
• List A, Dewald G, Bennett J, et al. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med. 2006;355(14):1456–1465. doi:10.1056/NEJMoa06129217021321
   PubMed Web of Science ®Google Scholar
• Fenaux P, Giagounidis A, Selleslag D, et al. A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q. Blood. 2011;118(14):3765–3776. doi:10.1182/blood-2011-01-33012621753188
   PubMed Web of Science ®Google Scholar
• Giagounidis A, Mufti GJ, Mittelman M, et al. Outcomes in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with isolated deletion 5q treated with lenalidomide: a subset analysis from the MDS-004 study. Eur J Haematol. 2014;93(5):429–438. doi:10.1111/ejh.1238024813620
   PubMed Web of Science ®Google Scholar
• Schuler E, Giagounidis A, Haase D, et al. Results of a multicenter prospective phase II trial investigating the safety and efficacy of lenalidomide in patients with myelodysplastic syndromes with isolated del (5q) (LE-MON 5). Leukemia. 2016;30(7):1580–1582. doi:10.1038/leu.2015.34026668126
   PubMed Web of Science ®Google Scholar
• Raza A, Reeves JA, Feldman EJ, et al. Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q. Blood. 2008;111(1):86–93. doi:10.1182/blood-2007-01-06883317893227
   PubMed Web of Science ®Google Scholar
• Toma A, Kosmider O, Chevret S, et al. Lenalidomide with or without erythropoietin in transfusion-dependent erythropoiesis-stimulating agent-refractory lower-risk MDS without 5q deletion. Leukemia. 2016;30(4):897–905. doi:10.1038/leu.2015.29626500139
   PubMed Web of Science ®Google Scholar
• Jädersten M, Saft L, Smith A, et al. TP53 mutations in low-risk myelodysplastic syndromes with del (5q) predict disease progression. J Clin Oncol. 2011;29(15):1971–1979. doi:10.1200/JCO.2010.31.857621519010
   PubMed Web of Science ®Google Scholar
• Mossner M, Jann JC, Nowak D, et al. Prevalence, clonal dynamics and clinical impact of TP53 mutations in patients with myelodysplastic syndrome with isolated deletion (5q) treated with lenalidomide: results from a prospective multicenter study of the german MDS study group (GMDS). Leukemia. 2016;30(9):1956–1959. doi:10.1038/leu.2016.11127133825
   PubMed Web of Science ®Google Scholar
• Brunner AM, Weng S, Cronin A, et al. Impact of lenalidomide use among non-transfusion dependent patients with myelodysplastic syndromes. Am J Hematol. 2018;93(9):1119–1126. doi:10.1002/ajh.2516630033577
   PubMed Web of Science ®Google Scholar
• Zeidan AM, Al Ali NH, Padron E, Lancet J, List A, Komrokji RS. Lenalidomide treatment for lower risk nondeletion 5q myelodysplastic syndromes patients yields higher response rates when used before azacitidine. Clin Lymphoma Myeloma Leuk. 2015;15(11):705–710. doi:10.1016/j.clml.2015.08.08326440749
   PubMed Web of Science ®Google Scholar
• Zeidan AM, Klink AJ, McGuire M, Feinberg B. Treatment sequence of lenalidomide and hypomethylating agents and the impact on clinical outcomes for patients with myelodysplastic syndromes. Leuk Lymphoma. 2019;60(8):2050–2055. doi:10.1080/10428194.2018.155153830636526
   PubMed Web of Science ®Google Scholar
• Zeidan AM, Smith BD, Carraway HE, Gojo I, DeZern A, Gore SD. A phase 2 trial of high dose lenalidomide in patients with relapsed/refractory higher-risk myelodysplastic syndromes and acute myeloid leukaemia with trilineage dysplasia. Br J Haematol. 2017;176(2):241–247. doi:10.1111/bjh.1440727790720
   PubMed Web of Science ®Google Scholar
• Passweg JR, Giagounidis AA, Simcock M, et al. Immunosuppressive therapy for patients with myelodysplastic syndrome: a prospective randomized multicenter phase III trial comparing antithymocyte globulin plus cyclosporine with best supportive care–SAKK 33/99. J Clin Oncol. 2011;29(3):303–309.21149672
   PubMed Web of Science ®Google Scholar
• Sloand EM, Wu CO, Greenberg P, Young N, Barrett J. Factors affecting response and survival in patients with myelodysplasia treated with immunosuppressive therapy. J Clin Oncol. 2008;26(15):2505–2511. doi:10.1200/JCO.2007.11.921418413642
   PubMed Web of Science ®Google Scholar
• Molldrem JJ, Caples M, Mavroudis D, Plante M, Young NS, Barrett AJ. Antithymocyte globulin for patients with myelodysplastic syndrome. Br J Haematol. 1997;99(3):699–705. doi:10.1046/j.1365-2141.1997.4423249.x9401087
   PubMed Web of Science ®Google Scholar
• Stahl M, DeVeaux M, de Witte T, et al. The use of immunosuppressive therapy in MDS: clinical outcomes and their predictors in a large international patient cohort. Blood Advances. 2018;2(14):1765–1772. doi:10.1182/bloodadvances.201801941430037803
   PubMed Web of Science ®Google Scholar
• Christman JK. 5-Azacytidine and 5-aza-2ʹ-deoxycytidine as inhibitors of DNA methylation: mechanistic studies and their implications for cancer therapy. Oncogene. 2002;21(35):5483–5495. doi:10.1038/sj.onc.120569912154409
   PubMed Web of Science ®Google Scholar
• Thépot S, Ben Abdelali R, Chevret S, et al. A randomized phase II trial of azacitidine ± epoetin-β in lower-risk myelodysplastic syndromes resistant to erythropoietic stimulating agents. Haematologica. 2016;101(8):918–925. doi:10.3324/haematol.2015.14098827229713
   PubMed Web of Science ®Google Scholar
• Jabbour E, Short NJ, Montalban-Bravo G, et al. Randomized phase 2 study of low-dose decitabine vs low-dose azacitidine in lower-risk MDS and MDS/MPN. Blood. 2017;130(13):1514–1522. doi:10.1182/blood-2017-06-78849728774880
   PubMed Web of Science ®Google Scholar
• Zeidan AM, Zhu W, Stahl M, et al. RBC transfusion independence among lower risk MDS patients receiving hypomethylating agents: a population-level analysis. Leuk Lymphoma. 2019;60(13):3181–3187. doi:10.1080/10428194.2019.162270031170846
   PubMed Web of Science ®Google Scholar
• Carrancio S, Markovics J, Wong P, et al. An activin receptor IIA ligand trap promotes erythropoiesis resulting in a rapid induction of red blood cells and haemoglobin. Br J Haematol. 2014;165(6):870–882. doi:10.1111/bjh.1283824635723
   PubMed Web of Science ®Google Scholar
• Herbertz S, Sawyer JS, Stauber AJ, et al. Clinical development of galunisertib (LY2157299 monohydrate), a small molecule inhibitor of transforming growth factor-beta signaling pathway. Drug Des Devel Ther. 2015;9:4479–4499. doi:10.2147/DDDT.S86621
   PubMed Web of Science ®Google Scholar
• Komrokji R, Garcia-Manero G, Ades L, et al. Sotatercept with long-term extension for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes: a phase 2, dose-ranging trial. Lancet Haematol. 2018;5(2):e63–e72. doi:10.1016/S2352-3026(18)30002-429331635
   PubMed Web of Science ®Google Scholar
• Santini V, Valcárcel D, Platzbecker U, et al. Phase II study of the ALK5 inhibitor galunisertib in very low-, low-, and intermediate-risk myelodysplastic syndromes. Clin Cancer Res. 2019;25(23):6976–6985. doi:10.1158/1078-0432.CCR-19-133831481511
   PubMed Web of Science ®Google Scholar
• Feigenson M, Nathan R, Materna C, et al. Ker-050, a novel inhibitor of Tgfβ superfamily signaling, induces red blood cell production by promoting multiple stages of erythroid differentiation. Blood. 2020;136(Supplement 1):34.
   Google Scholar
• Garcia-Manero G, Griffiths EA, Steensma DP, et al. Oral cedazuridine/decitabine for MDS and CMML: a phase 2 pharmacokinetic/pharmacodynamic randomized crossover study. Blood. 2020;136(6):674–683. doi:10.1182/blood.201900414332285126
   PubMed Web of Science ®Google Scholar
• Wei AH, Döhner H, Pocock C, et al. The QUAZAR AML-001 maintenance trial: results of a phase iii international, randomized, double-blind, placebo-controlled study of CC-486 (oral formulation of azacitidine) in patients with Acute Myeloid Leukemia (AML) in first remission. Blood. 2019;134(Supplement_2):LBA-3-LBA-3. doi:10.1182/blood-2019-132405
   PubMed Web of Science ®Google Scholar
• Guillermo Garcia-Manero VS, Almeida A, Platzbecker U, et al. Aristoteles Giagounidis. Abstract: A phase III placebo-controlled trial of CC-486 in patients with red blood cell transfusion-dependent (RBC-TD) anemia and thrombocytopenia due to IPSS lower-risk myelodysplastic syndromes (LR-MDS). EHA Library. 2020.
   Google Scholar
• Lange K, Holm L, Vang Nielsen K, et al. Telomere shortening and chromosomal instability in myelodysplastic syndromes. Genes Chromosomes Cancer. 2010;49(3):260–269. doi:10.1002/gcc.2073719998444
   PubMed Web of Science ®Google Scholar
• Park HS, Choi J, See CJ, et al. Dysregulation of Telomere Lengths and Telomerase Activity in Myelodysplastic Syndrome. Ann Lab Med. 2017;37(3):195–203. doi:10.3343/alm.2017.37.3.19528224765
   PubMed Web of Science ®Google Scholar
• Röth A, Harley CB, Baerlocher GM. Imetelstat (GRN163L)–telomerase-based cancer therapy. Recent Results Cancer Res. 2010;184:221–234.20072842
   PubMedGoogle Scholar
• Gürkan E, Tanriverdi K, Başlamişli F. Telomerase activity in myelodysplastic syndromes. Leuk Res. 2005;29(10):1131–1139. doi:10.1016/j.leukres.2005.03.00616111531
   PubMed Web of Science ®Google Scholar
• Baerlocher GM, Oppliger Leibundgut E, Ottmann OG, et al. Telomerase inhibitor imetelstat in patients with essential thrombocythemia. N Engl J Med. 2015;373(10):920–928. doi:10.1056/NEJMoa150347926332546
   PubMed Web of Science ®Google Scholar
• Tefferi A, Lasho TL, Begna KH, et al. A pilot study of the telomerase inhibitor imetelstat for myelofibrosis. N Engl J Med. 2015;373(10):908–919. doi:10.1056/NEJMoa131052326332545
   PubMed Web of Science ®Google Scholar
• Fenaux PSD, Van Eygen K, Raza A, et al. Abstract: treatment with imetelstat provides durable transfusion independence (TI) in heavily transfused non-del (5q) lower risk MDS (LR-MDS) relapsed/refractory (R/R) to erythropoiesis stimulating agents (ESAS). EHA Library. 2019.
   Google Scholar
• Chen N, Hao C, Peng X, et al. Roxadustat for anemia in patients with kidney disease not receiving dialysis. N Engl J Med. 2019;381(11):1001–1010. doi:10.1056/NEJMoa181359931340089
   PubMed Web of Science ®Google Scholar
• Yang Y, Yu X, Zhang Y, et al. Hypoxia-inducible factor prolyl hydroxylase inhibitor roxadustat (FG-4592) protects against cisplatin-induced acute kidney injury. Clin Sci (Lond). 2018;132(7):825–838. doi:10.1042/CS2017162529581249
   PubMed Web of Science ®Google Scholar
• Besarab A, Provenzano R, Hertel J, et al. Randomized placebo-controlled dose-ranging and pharmacodynamics study of roxadustat (FG-4592) to treat anemia in nondialysis-dependent chronic kidney disease (NDD-CKD) patients. Nephrol Dial Transplant. 2015;30(10):1665–1673. doi:10.1093/ndt/gfv30226238121
   PubMed Web of Science ®Google Scholar
• Pergola PE, Spinowitz BS, Hartman CS, Maroni BJ, Haase VH. Vadadustat, a novel oral HIF stabilizer, provides effective anemia treatment in nondialysis-dependent chronic kidney disease. Kidney Int. 2016;90(5):1115–1122. doi:10.1016/j.kint.2016.07.01927650732
   PubMed Web of Science ®Google Scholar
• Ariazi JL, Duffy KJ, Adams DF, et al. Discovery and preclinical characterization of GSK1278863 (daprodustat), a small molecule hypoxia inducible factor-prolyl hydroxylase inhibitor for Anemia. J Pharmacol Exp Ther. 2017;363(3):336–347. doi:10.1124/jpet.117.24250328928122
   PubMed Web of Science ®Google Scholar
• Kansagra KA, Parmar D, Jani RH, et al. Phase I clinical study of ZYAN1, A novel Prolyl-Hydroxylase (PHD) inhibitor to evaluate the safety, tolerability, and pharmacokinetics following oral administration in healthy volunteers. Clin Pharmacokinet. 2018;57(1):87–102. doi:10.1007/s40262-017-0551-328508936
   PubMed Web of Science ®Google Scholar
• Flamme I, Oehme F, Ellinghaus P, Jeske M, Keldenich J, Thuss U. Mimicking hypoxia to treat anemia: HIF-stabilizer BAY 85-3934 (Molidustat) stimulates erythropoietin production without hypertensive effects. PLoS One. 2014;9(11):e111838. doi:10.1371/journal.pone.011183825392999
   PubMed Web of Science ®Google Scholar
• Henry DH, Glaspy J, Harrup RA, et al. Roxadustat (FG4592; ASP1517; AZD9941) in the treatment of anemia in patients with Lower Risk Myelodysplastic Syndrome (LR-MDS) and Low Red Blood Cell (RBC) Transfusion Burden (LTB). Blood. 2019;134(Supplement_1):843. doi:10.1182/blood-2019-12871431488460
   PubMed Web of Science ®Google Scholar
• Zeidan AM, Stahl M, Sekeres MA, Steensma DP, Komrokji RS, Gore SD. A call for action: increasing enrollment of untreated patients with higher-risk myelodysplastic syndromes in first-line clinical trials. Cancer. 2017;123(19):3662–3672. doi:10.1002/cncr.3090328759108
   PubMed Web of Science ®Google Scholar